factor

(redirected from stem cell factor)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Factor

A financial institution that buys a firm's accounts receivable and collects the accounts.

Factor

A third party that buys a firm's accounts receivable. If a firm is not confident in its ability to collect on its credit sales, it may sell the right to receive payment to the factor at a discount. The factor then assumes the credit risk associated with the accounts receivable. This provides the firm immediate access to working capital, which is important, especially if the firm has a cash flow problem. The price of factoring is determined by the creditworthiness of the firm's customer, not of the firm itself. It is also known as accounts receivable financing.

factor

A firm that purchases accounts receivable from another firm at a discount. The purchasing firm then attempts to collect the receivables.

factor

To sell accounts receivable to another party at a discount from face value. Thus, a firm in need of cash to pay down short-term debt may decide to factor its accounts receivable to another firm.

factor

  1. a firm that purchases TRADE DEBTS from client firms. See FACTORING.
  2. a firm that buys in bulk and performs a WHOLESALING function.
  3. an input (for example raw material, labour, capital) which is used to produce a good or provide a service.

factor

  1. 1a FACTOR INPUT that is used in production (see NATURAL RESOURCES, LABOUR, CAPITAL).
  2. a business that buys in bulk and performs a WHOLESALING function.
  3. a business that buys trade debts from client firms (at some agreed price below the nominal value of the debts) and then arranges to recover them for itself. See FACTOR MARKET, FACTORING.
References in periodicals archive ?
Stem cell factor (c-KIT ligand) failed to show staining within the epithelium or subepithelium of small and large airways in all cases despite strong internal control staining of interstitial macrophages.
Their findings point to a relationship between the cKit receptor found on mast cells and the transmembrane stem cell factor (SCF) ligand found on metastatic breast cancer cells.
In 2002, Amgen granted ViaCell a non-exclusive worldwide license to Stem Cell Factor (SCF), a novel growth factor developed by Amgen, for ex vivo therapeutic uses.
We further investigated the roles of proliferation of epithelium and a possible stromal stem cell in induction of pulmonary PT by immunostaining for proliferating index (Ki-67) and thyroid transcription factor 1 (TTF-1) (11) and c-Kit antigen (a stem cell factor receptor/mast cell growth factor receptor).
Other studies by the two research groups have now determined safe doses of a newer growth-factor product, human stem cell factor, which is produced by genetically engineered bacteria.
The proto-oncogene c-kit encodes a 145-kd transmembrane tyrosine kinase receptor (CD117), the ligand of which is stem cell factor (SCF).
The receptor tyrosine kinase Kit and its natural ligand stem cell factor play an important role in normal blood cell production, gut function, pigmentation, and reproduction.